Edition:
United States

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

313.15INR
5:21am EST
Change (% chg)

Rs-0.05 (-0.02%)
Prev Close
Rs313.20
Open
Rs314.95
Day's High
Rs315.00
Day's Low
Rs310.70
Volume
884,693
Avg. Vol
1,092,331
52-wk High
Rs432.50
52-wk Low
Rs305.95

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Vaccine Vaxirab N Gets Prequalification From WHO
Friday, 15 Feb 2019 04:08am EST 

Feb 15 (Reuters) - Cadila Healthcare Ltd ::PURIFIED CHICK EMBRYO CELL RABIES VACCINE, VAXIRAB N, HAS RECEIVED PREQUALIFICATION FROM WORLD HEALTH ORGANISATION.  Full Article

India's Cadila Healthcare Dec-Qtr Consol Profit Falls
Thursday, 7 Feb 2019 03:43am EST 

Feb 7 (Reuters) - Cadila Healthcare Ltd ::DEC QUARTER CONSOL NET PROFIT 5.11 BILLION RUPEES VERSUS PROFIT OF 5.43 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 4.73 BILLION RUPEES.DEC QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 35.78 BILLION RUPEES VERSUS 32.60 BILLION RUPEES LAST YEAR.  Full Article

India's CCI Approves Acquisition Of Heinz Businesses Related To Glucon-D, Nycil, Sampriti Ghee and Complan Brands By Zydus/Cadila
Tuesday, 11 Dec 2018 06:30am EST 

Dec 11 (Reuters) - Competition Commission Of India::APPROVES ACQUISITION OF HEINZ BUSINESSES RELATED TO 4 BRANDS GLUCON-D, NYCIL, SAMPRITI GHEE,COMPLAN BY ZYDUS/CADILA.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Lansoprazole, Linagliptin Tablets
Thursday, 29 Nov 2018 01:41am EST 

Nov 29 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES APPROVALS FROM USFDA FOR LANSOPRAZOLE TABLETS AND LINAGLIPTIN TABLETS.ZYDUS GETS FINAL USFDA APPROVAL FOR LANSOPRAZOLE TABLETS AND TENTATIVE APPROVAL FOR LINAGLIPTIN TABLETS.LANSOPRAZOLE WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.LINAGLIPTIN WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets Final Approval From USFDA For Baclofen Tablets
Tuesday, 27 Nov 2018 03:33am EST 

Nov 27 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM THE USFDA FOR BACLOFEN TABLETS.BACLOFEN TABLETS IS USED TO TREAT MUSCLE SPASMS CAUSED BY CONDITIONS SUCH AS MULTIPLE SCLEROSIS, SPINAL CORD INJURY/DISEASE.BACLOFEN TABLETS WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT BADDI.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Nod For Two Drugs
Thursday, 22 Nov 2018 03:58am EST 

Nov 22 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES APPROVALS FROM USFDA FOR ATORVASTATIN CALCIUM TABLETS AND DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES.ATORVASTATIN DRUG TO BE MANUFACTURED AT FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD.ATORVASTATIN IS USED TO HELP LOWER BAD CHOLESTEROL AND FATS AND RAISE GOOD CHOLESTEROL IN THE BLOOD.DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES WILL BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.DIMETHYL FUMARATE DRUG INDICATED FOR TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS.  Full Article

Cadila Healthcare Says Zydus Gets Tentative Approval From USFDA For Deferasirox Tablets
Tuesday, 20 Nov 2018 01:40am EST 

Nov 20 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DEFERASIROX TABLETS.  Full Article

Cadila Healthcare Says Zydus Gets USFDA Final Approval For Abacavir & Lamivudine Tablets
Friday, 16 Nov 2018 02:18am EST 

Nov 16 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE - ZYDUS GETS FINAL APPROVAL FROM THE USFDA FOR ABACAVIR & LAMIVUDINE TABLETS AND FONDAPARINUX SODIUM INJECTION.WILL BE MANUFACTURED AT THE GROUP’S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Updates On News Item On Drug Of Substandard Quality
Monday, 12 Nov 2018 09:12am EST 

Nov 12 (Reuters) - Cadila Healthcare Ltd ::CLARIFIES ON NEWS ITEM ON DRUG OF SUBSTANDARD QUALITY.GOT LETTER ON 22 JUNE FROM ASSISTANT DRUG CONTROLLER, KOCHI DECLARING ZIPCET TABLETS BATCH WAS NOT OF A STANDARD QUALITY.HAD RECALLED BATCH FROM MARKET ON JUNE 29.  Full Article

Zydus Wellness Says Deal To Buy Heinz India Expected To Be EPS Accretive
Wednesday, 24 Oct 2018 03:04am EDT 

Oct 24 (Reuters) - Zydus Wellness Ltd ::DEAL TO BUY HEINZ INDIA IS EXPECTED TO BE EPS ACCRETIVE.DEAL ALSO INCLUDE 2 LARGE MANUFACTURING FACILITIES IN ALIGARH, SITARGANJ, TEAMS FOR OPERATIONS, RESEARCH, SALES,MARKETING AND SUPPORT.  Full Article

UPDATE 2-Kraft Heinz to sell part of India business for about $630 mln

* Deal does not assume any debt (Recasts throughout to add background, deal details)